It has been reported that MeCP2 mutation determines growth disadvantage in cultured lymphocyte cells[6] and that its functional ablation suppresses cell growth of glial cells[7] and proliferation in mesenchymal stem cells[8] and prostate cancer cells[9,10]. This evidence concerns the gene MECP2 and prostate cancer.